It also strikingly decreases the levels of Nrf2 inhibitor, Keap1 protein.Therefore, the crosstalk between p62/SQSTM1 and Nrf2 could be therapeutically exploited to increase cancer patient response to therapies [31]. This evidence concerns the gene KEAP1 and cancer.